% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • censored53 censored53 Aug 27, 2013 8:49 AM Flag

    Doing the Math for the Math and/or Integrity Challenged


    A manufactured market cap of 2,650 million, trailing twelve month revenue (sales) of 7.72 million which netted 73 million in losses…and the basis for the astronomical price, a treatment (not cure) for a genetic high cholesterol disorder that effects one in a million that fewer than one in a thousand of those afflicted will be able to afford based upon the 300K annual price tag.

    United States 316,668,567 (July 2013 est.)
    European Union 503,890,016 (July 2013 est.)
    World 7,095,217,980 (July 2013 est.)

    One in a million afflicted means potential of 317 in USA, 504 in EU, or 7,095 prescriptions worldwide. How many of those do you think can afford ANNUAL 300K prescription?

    GDP per Capita
    United States $50,700 (2012 est.)
    European Union $35,100 (2012 est.)
    World $12,700 (2012 est.)

    Per IRS statistics, applying affordability, the income cutoff for the top 1% of people who filed income tax returns in 2009 was 344K (1.38 million people), being generous that means approximately 1 in 200 in the USA could if they chose afford the prescription....Worldwide I'd have to assume fewer than 1 in 1000 of those diagnosed will be able to afford the prescription.

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.485+0.075(+5.32%)2:07 PMEDT